PAB - Still in Preopen 3 Jul 2018 Patents Granted for Deoxymab...

PAB  - Still in Preopen

3 Jul 2018

Patents Granted for Deoxymab 3E10 Family in both Japan and China

Melbourne, Australia; July 3, 2018: Patrys Limited (ASX: PAB), a therapeutic antibody development company, is pleased to announce that it has received Notices of Grant from both the Japanese and Chinese Patent Offices for the patent titled “Cell-penetrating anti-DNA antibodies and uses thereof to inhibit DNA repair” (Patent numbers 6178785 (JP) and ZL 201280025431.2 (CN)). The patent is directed towards methods of using Patrys’ novel Deoxymab 3E10 technology, including Patrys’ lead candidate, PAT-DX1, as treatment for various cancers and malignancies including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.
Following grant in the U.S. of the first patent in the 3E10 portfolio in July 2017, both the Japanese and Chinese patents extend the intellectual property base of the Company.

“Grant of patents in the USA, Japan and China establishes strong intellectual property rights for the 3E10 technology in the world’s three largest pharmaceutical markets, and is another important step for Patrys.” said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys. “Patrys has made significant progress with its pre-clinical development of PAT-DX1 over the past year, including confirmation that PAT-DX1 can cross the blood-brain barrier, and improve survival in a mouse model of glioblastoma. Following-on from $4.6 million capital raise in May, the Company is in a strong position to achieve further milestones this year and we look forward to providing updates on our progress over the coming months.”